Abstracts tagged "Disease Activity"

Abstract Number: 2113 • ACR Convergence 2023
Impact of Sociodemographic Factors on Efficacy and Safety of Tofacitinib in Patients with Rheumatoid Arthritis: A Post Hoc Analysis of Phase 2/3/3b/4 Studies
Grace Wright¹, Eduardo Mysler², Kevin Roberts³, Lindsay Sweet⁴ and Ahmed Shelbaya⁵, ¹Grace C Wright MD PC, New York, NY, ²Organizacion Medica de Investigacion, Buenos Aires, Argentina, ³Pfizer Inc., Cambridge, MA, ⁴Pfizer Inc., Collegeville, PA, ⁵Pfizer Inc., New York, NY
Background/Purpose: Sociodemographic factors can impact treatment response and safety outcomes in patients (pts) with RA. Here, we explore the impact of sociodemographic index (SDI) on…
Abstract Number: 2273 • ACR Convergence 2023
Predicting SLE Disease Activity with Blood Biomarkers: A Step Towards Precision Medicine
Vasileios Kyttaris¹, Tyler O'Malley², Giorgio Casaburi², Sudha Kumar² and Andrew Concoff³, ¹BIDMC, Boston, MA, ²Exagen, Vista, CA, ³Exagen, Los Angeles, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is the prototypical autoimmune disease with diverse clinical manifestations and variable treatment response. Conventional biomarkers of SLE activityprovide modest correlation…
Abstract Number: 2541 • ACR Convergence 2023
Differential Responses to Initial Treatment Strategies for Rheumatoid Arthritis Among Those with Lower Body Mass and Adiposity
Joshua Baker¹, James O'Dell², Bryant England², Jon Giles³, Jefferey Newcomb⁴, Michael George¹, Geoffrey Thiele², Larry Moreland⁵, S. Louis Bridges⁶, Jeffrey R Curtis⁷ and Ted R Mikuls⁸, ¹University of Pennsylvania, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³Columbia University, New York, NY, ⁴University of Nebraska, Omaha, NE, ⁵University of Colorado, Denver, CO, ⁶Hospital for Special Surgery, New York, NY, ⁷Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, ⁸Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The identification of measures that help predict who is likely to benefit most from early escalation to biologic therapy would inform personalized care among…
Abstract Number: 0117 • ACR Convergence 2023
The Patient Journey to a First Diagnosis of Systemic Sclerosis: Temporal Disease Pattern Identification Using Machine Learning and Data Mining Among US and Japanese Patients
Francesco Del Galdo¹, Yahui Tian², Stefano Di Donato¹ and Mario Ehlers², ¹University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom, ²Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT
Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disease characterized by skin and organ fibrosis and vasculopathy. The Very Early Diagnosis of SSc (VEDOSS) project…
Abstract Number: 0388 • ACR Convergence 2023
Left Ventricular Geometry Abnormalities Are Related to Higher Clinical Activity in Rheumatoid Arthritis Patients
Victor Beltran¹, Iris Colunga², Dionicio A. Galarza-Delgado², José Ramón Azpiri-López², Jesus Alberto Cardenas-De la Garza³, Rosa Arvizu-Rivera⁴, Valeria Gonzalez-Gonzalez⁵ and Angel Arias Peralta⁶, ¹Rheumatology Service Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, ²Hospital Universitario UANL, Monterrey, Mexico, ³Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico, ⁴Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Mexico, ⁵Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁶Medicine Faculty, Universidad Autonoma De Nuevo Leon, Monterrey, Mexico
Background/Purpose: Rheumatoid arthritis (RA) leading cause of death is cardiovascular (CV) disease. RA patients can develop silent myocardial tissue alterations, which result in changes in…
Abstract Number: 0541 • ACR Convergence 2023
Treat-to-Target Strategy Implementation in Spondyloarthritis Patients of Real-World Clinical Practice: A Cross-Sectional Single-Center Study
Irini Flouri¹, Nestor Avgoustidis², Anastasios Eskitzis², Argyro Repa², Katerina Pateromichelaki², Sofia Pitsigavdaki³, Myrto Nikoloudaki², Maria Terizaki², George Bertsias⁴ and Prodromos Sidiropoulos⁴, ¹University of Crete Medical School, Heraklion, Greece, ²Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Heraklion, Greece, ³Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Crete, Greece, ⁴Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Greece; Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology Hellas (FORTH), Heraklion, Greece
Background/Purpose: Data regarding the adoption of the treat-to-target (T2T) approach aiming at inactive disease (ID), or low disease activity (LDA) in axial (axSpA) and peripheral…
Abstract Number: 0919 • ACR Convergence 2023
Investigating the Role of Interferon in Promoting Flares of SLE at a Single Cell Level
Zoha Faheem¹, Giselle Boukhaled², Kieran Manion¹, Carolina Munoz-Grajales³, Carol Nassar¹, Michael Kim¹, Dafna Gladman⁴, Murray Urowitz⁵, Zahi Touma⁶, David Brooks² and Joan Wither⁷, ¹Schroeder Arthritis Institute, Krembil Research Institute, Toronto, ON, Canada, ²Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, ³UHN/TWH, Toronto, ON, Canada, ⁴Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute; University of Toronto Lupus Clinic; Division of Rheumatology, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷University Health Network, Toronto, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with unpredictable flares interspersed with prolonged periods of disease quiescence. Interferon (IFN) is a hallmark…
Abstract Number: 1252 • ACR Convergence 2023
Physician Global Assessment of Disease Activity in Childhood-Onset Systemic Lupus Erythematosus – Does the Approach Matter?
Ekemini Ogbu¹, Hermine Brunner², Jennifer Huggins³, Angela Merritt³, Megan Quilan-Waters³, Catherine Robben³, Chen Chen³, Daniel J Lovell⁴ and Bin Huang³, ¹Cincinnati Children's Hospital Medical Center, University of Cincinnati School of Medicine, Johns Hopkins University, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴UC Department of Pediatrics, Cincinnati Children's Hospital, University of Cincinnati, Cincinnati, OH
Background/Purpose: Physician Global Assessment of Disease Activity (PhGA) are commonly used outcome measures in pediatric rheumatology. For childhood-onset systemic lupus erythematosus (cSLE), the traditional visual…
Abstract Number: 1391 • ACR Convergence 2023
Rates of Remission in Patients with Axial Spondyloarthritis Treated in Tertiary Care
Franziska Neinert¹, Imke Redeker², Styliani Tsiami¹, David Kiefer¹, Barbara Guminski¹, Xenofon Baraliakos³, Juergen Braun¹ and Uta Kiltz⁴, ¹Ruhr-Universität Bochum and Rheumazentrum Ruhrgebiet, Herne, Germany, ²Ruhr Universität Bochum, Bochum, Germany, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: Achieving remission is the treatment target for patients (pts.) with axial spondyloarthritis (axSpA).Remission rates over longer periods in a real-life setting have not been…
Abstract Number: 1530 • ACR Convergence 2023
Outcomes in Patients with Systemic Sclerosis Following Lung Transplantation: An Italian Multicentre Experience
Claudia Iannone¹, Maria Rosa Pellico¹, Letizia Corinna Corinna Morlacchi², Valeria Rossetti², Marco Vicenzi², Paolo Airò³, Marta Saracco⁴, Annamaria iagnocco⁴, Lorenzo Beretta⁵, Adriana Severino⁵, Eleonora Zaccara⁶, paola Faggioli⁶, Fabio Cacciapaglia⁷, Stefano Stano⁸, Silvia Cavalli⁹, Antonina Minniti⁹, giorgia Trignani⁹, francesco Blasi⁵, Roberto F. Caporali¹⁰ and Nicoletta Del Papa¹¹, ¹ASST Gaetano Pini CTO, Milan, Italy, ²Policlinico di Milano, Milan, Italy, ³Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy, ⁴AO Mauriziano di Torino, Torino, Italy, ⁵Policlinico di Milano, Milano, Italy, ⁶Legnano-ASST-Ovest Milanese, Legnano, Italy, ⁷Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari, Bari, Italy, ⁸Policlinico di Bari, Bari, Italy, ⁹ASST Gaetano Pini CTO, Milano, Italy, ¹⁰Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milano, Italy, ¹¹Scleroderma Clinic, Dipartimento di Reumatologia, ASST Gaetano Pini CTO, Milano, Italy
Background/Purpose: Lung transplantation (LT) is gaining ground in managing advanced ILD in SSc patients. However, concerns remain among surgeons due to SSc's complexity, multiorgan involvement…
Abstract Number: 2117 • ACR Convergence 2023
Frailty Is Associated with Mortality in Veterans with Rheumatoid Arthritis
Sayuli Bhide¹, Punyasha Roul², Namrata Singh³, Grant Cannon⁴, Gary Kunkel⁵, Ted R Mikuls⁶, Bryant England², Dolores Shoback⁷, Patti Katz⁸, Jose Garcia⁹, Ariela Orkaby¹⁰, Joshua Baker¹¹ and K Wysham¹², ¹University of Washington, Seattle, WA, ²University of Nebraska Medical Center, Omaha, NE, ³University of Washington, Bellevue, WA, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵University of Utah, Salt Lake City, UT, ⁶Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁷San Francisco VA Medical Center, San Francisco, CA, ⁸University of California San Francisco, San Rafael, CA, ⁹VA Puget Sound Healthcare System, Seattle, WA, ¹⁰Veterans Affairs Boston Healthcare System & Brigham and Women’s Hospital, Harvard Medical School, Boston, MA; VA Geriatric Research Education and Clinical Center, Boston, MA, ¹¹University of Pennsylvania, Philadelphia, PA, ¹²VA Puget Sound/University of Washington, Seattle, WA
Background/Purpose: Frailty is established as an important predictor of mortality in the general population.1Rheumatoid arthritis (RA) is associated with higher rates of frailty than the…
Abstract Number: 2280 • ACR Convergence 2023
The LFA-REAL Clinician Reported Outcome Predicts Damage in Patients with Systemic Lupus Erythematosus (SLE). Data from a Prevalent Latin American Lupus Cohort
Manuel Ugarte-Gil¹, Rocío Gamboa-Cárdenas², Victor Pimentel-Quiroz², Cristina Reategui-Sokolova³, Claudia Elera-Fitzcarrald⁴, Erika Noriega⁵, Cesar Pastor-Asurza⁶, Zoila Rodriguez-Bellido⁶, Risto Perich-Campos⁶ and Graciela S Alarcón⁷, ¹Universidad Cientifica del Sur, Lima, Peru, ²Universidad Cientifica del Sur/Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, ³Hospital Guillermo Almenara Irigoyen, EsSalud/Universidad San Ignacio de Loyola, Lima, Peru, ⁴Hospital Guillermo Almenara Irigoyen, EsSalud/Universidad Privada San Juan Bautista, Lima, Peru, ⁵Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, ⁶Hospital Guillermo Almenara Irigoyen, EsSalud/Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁷Heersink School of Medicine. The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The Lupus Foundation of America Rapid Evaluation of Activity in Lupus (LFA-REAL) clinican-reported outcome (ClinRO) correlates well with other disease activity indices such us…
Abstract Number: 2551 • ACR Convergence 2023
Remission and Low Disease Activity (LDA) in Patients with SLE Treated with Belimumab (BEL): Results from a Large Integrated Analysis
Ioannis Parodis¹, Julius Lindblom¹, Roger A. Levy², Margherita Zen³, Nursen Cetrez¹, Alvaro Gomez⁴, Shereen Oon⁵, Christine Henning⁶, Munther Khamashta⁷, Holly A. Quasny⁸, Deven Chauhan⁹, Anca Askanase¹⁰, Ronald van Vollenhoven¹¹ and Mandana Nikpour¹², ¹Karolinska Institutet, Stockholm, Sweden, ²GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, ³University of Padua, Division of Rheumatology, Department of Medicine, Padua, Italy, ⁴Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ⁵University of Melbourne at St Vincent’s Hospital, Departments of Rheumatology and Medicine, Fitzroy, Australia, ⁶GlaxoSmithKline, US Medical Affairs, Durham, NC, ⁷GSK Gulf, Medical Affairs Department, Dubai, United Arab Emirates, ⁸GlaxoSmithKline, Research & Development, Durham, NC, ⁹GlaxoSmithKline, Value Evidence and Outcomes, Brentford, United Kingdom, ¹⁰Columbia University Medical Center, New York, NY, ¹¹Amsterdam Rheumatology and Immunology Center and Amsterdam University Medical Centers, Department of Rheumatology, Amsterdam, Netherlands, ¹²The University of Melbourne at St. Vincent’s Hospital Melbourne, Departments of Medicine and Rheumatology, Melbourne, Australia
Background/Purpose: A key treatment goal in SLE management is the attainment of remission or LDA,1 for which various definitions exist, including “Definitions of Remission in…
Abstract Number: 0157 • ACR Convergence 2023
Discovering the Potential of Digital Biomarkers in the Work Process of the Rheumatology Healthcare Professionals, a Design Thinking Approach; Preliminary Results of the Healthcare Professionals Perspective
patty de Groot¹, Jolanda J. Luime¹, Marc r. Kok², marijn vis¹ and ilja Tchetverikov³, ¹Erasmus Medical Center, Rotterdam, Netherlands, ²Maasstad Hospital, Rotterdam, Netherlands, ³Albert Sweitzer Hospital, Dordrecht, Netherlands
Background/Purpose: During times of social-distancing, in-person outpatient visits were greatly reduced. Health care professionals (HCPs) were dependent on the patient's reported experience of their disease…
Abstract Number: 0398 • ACR Convergence 2023
Identification of Disease Activity-related miRNAs Through Artificial Neural Network Analysis in Rheumatoid Arthritis
Milena Rodriguez Alvarez¹, Lissette Delgado-Cruzata², Anna Tryfonos¹, Nickolas Almodovar², Toni-Ann Bravo² and Naureen Kabani¹, ¹SUNY Downstate Health Sciences University, Brooklyn, NY, ²The City University of New York, John Jay College, New York, NY
Background/Purpose: Rheumatoid Arthritis (RA) is the result of the complex interplay between genetic, epigenetic, and environmental factors leading to immune dysregulation, synovial membrane inflammation, and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.